What is 5-Amino-1MQ? A Research Guide.

5-Amino-1MQ is discussed among inhibitors of nicotinamide N-methyltransferase, or NNMT. Although grouped with peptides in some catalogs, it belongs to a different chemical class; a product format does not determine whether a substance is a peptide.[1]

NNMT catalyses a methylation reaction involving nicotinamide and a methyl donor. The cited inhibitor study measured the reaction product 1-MNA and related metabolites such as NAD+ and SAM in cultured adipocytes. Reducing an enzyme’s reaction product provides evidence of target engagement; it is not identical to improving a clinical outcome. The research connects enzyme inhibition with changes in cellular metabolism, while leaving the human translation question open.[1][2]

The primary paper examines small-molecule NNMT inhibitors in mouse metabolic models. The review places NNMT within broader metabolic research. These sources concern experimental targets and compounds under defined laboratory conditions.[1]

The primary paper assessed membrane permeability and selectivity of a series of methylquinolinium inhibitors, then examined adipocyte metabolism and diet-induced obese mice. It reported lower 1-MNA, changes in cellular metabolites and reduced adipose-related measures in the mouse experiments. Those findings concern the specified chemical series and models. The exact compound used in a particular experiment must be checked rather than treating all NNMT inhibitors as interchangeable.[1][2]

Results in mice and proposed enzyme mechanisms do not establish clinical weight-loss effects or safety in people. Evidence about an inhibitor class must also be checked against the exact compound; related inhibitors need not have identical properties.[1][2]

The cited source set does not validate a human regimen or the afiya product. It also does not justify treating NNMT inhibition as equivalent to taking NAD+ or any peptide in the catalog.

The authors’ observation of no obvious adverse effects in their mouse experiments is not a complete toxicology assessment or human safety finding. Enzyme selectivity, broader metabolic effects and long-term exposure require additional evaluation. No human benefit or product-specific safety claim follows from a preclinical target-validation study.[1][2]